triple hormone receptor agonist retatrutide for obesity Eli Lilly and Company's agonist, retatrutide, successful in two additional phase 3 trials, delivering significant improvements in weight and A1C Retatrutide triple hormone receptor agonist
Pay in 4 interest-free payments of $5.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28

















![Metapod (54/102) (Shadowless) [Base Set 1st Edition] U-WTR044](https://cdn.shopify.com/s/files/1/0605/1722/0547/files/96ae2b30-067c-4463-9d0e-d53d1e32ea69.png?v=1736062005)
![Switch (95/102) (Shadowless) [Base Set 1st Edition] U-MON000-RF](https://cdn.shopify.com/s/files/1/0605/1722/0547/files/772bcc8f-2834-4075-b84b-d8572db9f4bd.png?v=1741280666)


